| 朱方,赵慧慧,蒋文,等.卡瑞利珠单抗治疗晚期非小细胞肺癌致内分泌系统不良反应临床观察[J].安徽医药,2023,27(9):1904-1908. |
| 卡瑞利珠单抗治疗晚期非小细胞肺癌致内分泌系统不良反应临床观察 |
| Clinical observation of endocrine system adverse reactions related to camrelizumab treatment for advanced non-small cell lung cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2023.09.047 |
| 中文关键词: 癌，非小细胞肺 药物相关性副作用和不良反应 程序性死亡受体 -1 卡瑞利珠单抗 免疫相关不良反应 |
| 英文关键词: Carcinoma, non-small-cell lung Drug-related side effects and adverse reactions Programmed death receptor-1 Camrelizumab Immune-related adverse reactions |
| 基金项目: |
|
| 摘要点击次数: 733 |
| 全文下载次数: 273 |
| 中文摘要: |
| 目的探讨程序性死亡受体( PD-1)抑制剂卡瑞利珠单抗治疗晚期非小细胞肺癌过程中内分泌系统的免疫相关不良反应( irAEs)的临床情况。方法回顾性分析 2019年 1月 1日至 2021年 12月 31日南京市第二医院收治的共 86例接受卡瑞利珠单抗治疗的晚期非小细胞肺癌病人，观察治疗期间发生的内分泌系统不良反应，包括甲状腺功能减退症(甲减)、甲状腺功能亢进症(甲亢)、垂体炎、 1型糖尿病、甲状旁腺功能亢进症(甲旁亢)或甲状旁腺功能减退症(甲旁减)等。结果 86例病人中， 17例( 19.8%)发生内分泌系统 irAEs，其中甲减 11例( 1~2级 10例， 3级 1例)甲亢 2例( 1级)甲状腺炎 1例( 1级)1型糖尿病 1例( 3级)垂体炎 1例( 2级)甲旁亢 1例( 3级)甲旁减 0例，未见4级及以上内，分泌系统不良反，应。发生内分泌系统，不良反应的中位时间，为首次卡瑞利珠单，抗治疗后 13.1周。，2级及以下 irAEs病人经对应治疗后均可以继续接受卡瑞利珠单抗治疗， 3级irAEs病人后续根据具体情况可考虑停用卡瑞利珠单抗。结论在使用卡瑞利珠单抗过程中，发生内分泌系统 irAEs风险相对较高，其中尤以甲状腺功能障碍发生率较高；但定期监测、及时治疗是安全可控的。 |
| 英文摘要: |
| Objective To explore the clinical situation of immune-related adverse reactions (irAEs) in the endocrine system during the treatment of advanced non-small cell lung cancer with the programmed death receptor (PD-1) inhibitor camrelizumab.Methods A total of 86 patients with advanced non-small cell lung cancer (NSCLC) who received camrelizumab treatment from January 1, 2019 toDecember 31, 2021, at Nanjing Second Hospital were retrospectively analyzed. The adverse reactions of the endocrine system, includ-ing hypothyroidism (hypothyroidism), hyperthyroidism (hyperthyroidism), pituitary gland inflammation, type 1 diabetes mellitus, hyper-parathyroidism (hyperparathyroidism), or hypoparathyroidism (hypoparathyroidism), occurring during the treatment period were ob-served.Results Among 86 patients, endocrine system irAEs occurred in 17 cases (19.8%), including 11 cases of hypothyroidism (10 cases of grade 1-2 and 1 case of grade 3), 2 cases of hyperthyroidism (grade 1), 1 case of thyroiditis (grade 1), 1 case of type 1 diabetesmellitus (grade 3), 1 case of pituitary inflammation (grade 2), 1 case of hyperparathyroidism (grade 3), and 0 cases of hypoparathyroid-ism. No grade 4 or above endocrine system adverse reactions were observed. The median time to occurrence of endocrine system ad-verse reactions was 13.1 weeks after the first camrelizumab treatment; patients with grade 2 and lower irAEs can continue to receivecamrelizumab after corresponding treatment; patients with grade 3 irAEs can be considered for subsequent discontinuation of camreli-zumab on a case-by-case basis.Conclusion Endocrine system irAEs are at relatively high risk during the use of camrelizumab, with aparticularly high incidence of thyroid dysfunction, but regular monitoring and timely treatment are safe and controllable. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
